Ann: Voluntary Suspension, page-435

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 435 Last

Share
Profile

Follow
GCInvestor

5,398 Posts.

1239

09/08/17

07:55

Post #: 26377254
Share

Originally posted by mariolordz ↑

Whether you're on the positive or negative side of this debate, the following is very clear:

1. The idea is compelling, has many applications and overall great potential.

2. At present, the company has no earnings. It's present valuation at 200 million is purely speculative.

3. Initial holders have long since sold out of the business.

4. The voluntary suspension to delay a week, followed a TH which in itself represented a delay of over a month on the expectation clearly set by management for delivery of results.

Two things are clear...

1. Given the speculative valuation, and management's language around these results, they are absolutely critical to the SP, which means...

2. IF trading resumes (i.e. they don't extend the VS), no matter what the result, we'll see a big SP shift.

Personally, the fact that many initial holders have sold out of the business, prior to what was purported to be the biggest windfall (results/FDA) was cause enough for caution (hence my holding is relatively small). However, following management's consistent failure to meet expectations on delivery dates and with a zero cash flow valuation of 200 million, I'm less certain that even my small exposure is worth the risk.

Time will tell...

Expand

Sorry, but I beg to differ .... "initial holders have long since sold out" ... I have been in since 1.8 cents and so have a hell of a lot of others that regularly contribute to this forum .... other than wiseone, who are you referring to?

RAP Price at posting: 31.0¢ Sentiment: Buy Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

HLX

Helix investor makes partial takeover bid, proposing board changes

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

EBR

EBR reaches review milestone for wireless cardiac pacing device

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Results wrap: Austal, TPG Telecom and Downer